---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002557"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-01-16T23:59:59+00:00"
generated_at: "2026-05-16T09:54:03.330599+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded

## Summary
- Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.
- Initial $900k funded; additional advances possible until Feb 16, 2026 outside date for proposed equity financing.
- Principal converts dollar-for-dollar into equity instruments of proposed Subsequent Financing; no interest unless default (then 15%).
- Company expects to close $5.5M equity financing by Feb 16, 2026; note supports that process.

## SEC filing metadata
- accession: 0001493152-26-002557
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-01-16T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/0001493152-26-002557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002557
- JSON: https://secwatch.observer/filing/0001493152-26-002557.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002557.txt

## Key facts
- Material Agreements
  Vivos Therapeutics, Inc. entered into Note with V-Co Investors 3 LLC valued at up to $5,500,000 (effective 2026-01-15).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: V-Co Investors 3 LLC
  - Value: up to $5,500,000
  - Effective: 2026-01-15
  source text: On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/0001493152-26-002557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.